The Protean laboratory Protean has participated in the development of new diagnostic kits used for the detection of Lyme disease. The tests contain highly specific recombinant antigens isolated from Borrelia strains that can be found in the Czech Republic. The recombinant antigens developed by Protean exclude cross reactions with other spirochete bacteria, and the tests thus show higher specificity and a higher chance of disease detection than competitive tests.
For reliable detection of antibodies in the blood, we advise you to choose a laboratory where these tests are used. The manufacturer of the tests is VIDIA s.r.o.
Our ELISA-VIDTEST anti-Borrelia recombinant kits are designed for detection of specific IgG and IgM antibodies against antigens of the major pathogenic borrelia strains (B.afzelii, B.garinii and B.burgdorferi sensu stricto) in human serum. Antibody testing is one of the methods used in Lyme disease diagnosis. Lyme disease diagnosis is based on the combination of clinical and laboratory examination.
LIA-VIDTEST anti-Borrelia kits are Line ImmunoAssay kits designed for qualitative detection of specific IgG antibodies against antigens of major pathogenic Borrelia stains (B. afzelii, B. garinii and B. burgdorferi sensu stricto) and Anaplasma phagocytophila (causative agent of human granulocytic anaplasmosis – HGA or ehrlichiosis) in human serum. These are confirmative tests intended to validate the ELISA test results for serological diagnosis of Lyme disease. The kit can also be used as an additional test in HGA diagnosis.
IgM antibodies are created 3 weeks after infection, with maximum numbers present after 6 weeks. After that their level is slowly decreasing and the production of IgG antibodies begins. Antibody testing is important in the early phase of infection, especially when no typical symptoms appear (for example erythema migrans occurs only in cca 60% of cases). Some Lyme disease symptoms can resemble symptoms of other diseases, and therefore antibody testing is also used in differential diagnosis of neuroinfections, arthropathies, carditis and skin diseases.
When interpreting results, slow production of antibodies, possibility of previous antibiotics administration affecting antibody production, seronegativity in a small percentage of patients, and the possibility of cross reaction in patients with coinfections must be taken into consideration. Thus, results must always be compared with clinical examination.